Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 7/20 | 1.00 |
| ▸ | PARP11 | Q9NR21 | 6/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 0.68 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.68 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.68 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.68 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.68 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.68 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.68 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.68 |
| ▸ | PARP1 | P09874 | 14/20 | 0.64 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29644368 | 1.00 | PARP10 (1.00) | PARP10PARP11PIM1CSNK1A1CDK5 | |
| SCHEMBL19643333 | 0.89 | PARP10 (0.81) | PARP10PARP11PIM1CSNK1A1CDK5 | |
| Toluene SCHEMBL29027038 | 0.89 | PARP10 (0.79) | PARP10PARP11PIM1CSNK1A1CDK5 | |
| SCHEMBL1333810 | 0.81 | CLK4 (1.00) | PARP10PARP11PIM1CSNK1A1CDK5 | |
| SCHEMBL831538 | 0.78 | PARP1 (1.00) | PARP10PARP11PARP1PDPK1ACHE | |
| SCHEMBL797996 | 0.78 | PARP1 (0.64) | PARP10PARP11PARP1PDPK1ACHE | |
| SCHEMBL7581623 | 0.78 | PARP1 (1.00) | PARP10PARP11PIM1CSNK1A1CDK5 | |
| SCHEMBL6421827 | 0.78 | PARP1 (0.64) | PARP10PARP11PIM1CSNK1A1CDK5 | |
| SCHEMBL8118685 | 0.78 | PARP1 (0.64) | PARP10PARP11PIM1CSNK1A1CDK5 | |
| SCHEMBL830807 | 0.78 | PARP1 (1.00) | PARP10PARP11PIM1CSNK1A1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250296931-A1 | NOVEL ISOQUINOLINONE, PYRROLOPYRIDINONE AND THIENOPYRIDINONE SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2025-09-25 | — | — | US | disclosed |
| US-20240300907-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-09-12 | — | — | US | disclosed |
| WO-2024153112-A1 | PDE4 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | 瑞石生物医药有限公司 | 2024-07-25 | — | — | WO | disclosed |
| CN-114507181-B | Propionic acid compound containing 5-substituted tetrahydroisoquinoline, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2024-03-26 | — | — | CN | disclosed |
| WO-2024017856-A1 | NOVEL ISOQUINOLINONE, PYRROLOPYRIDINONE AND THIENOPYRIDINONE SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| CN-117242073-A | PRMT5 inhibitors and uses thereof | 海思科医药集团股份有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20100197725-A1 | 1-OXO-ISOINDOLINE-4-CARBOXAMIDE AND 1-OXO-1,2,3,4-TETRAHYDROISOQUINOLINE-5-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-05 | — | — | US | disclosed |
| US-20100173886-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173886-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| EP-2200989-A1 | ISOQUINOLINYL AND ISOINDOLINYL DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2010-06-30 | — | — | EP | disclosed |
| EP-2185511-A2 | 1-OXO-ISOINDOLINE-4-CARBOXAMIDE AND 1-OXO-1,2,3,4-TETRAHYDROISOQUINOLINE-5-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009044019-A2 | 1-OXO-ISOINDOLINE-4-CARBOXAMIDE AND 1-OXO-1,2,3,4-TETRAHYDROISOQUINOLINE-5-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009036144-A1 | ISOQUINOLINYL AND ISOINDOLINYL DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20090069300-A1 | ISOQUINOLINYL AND ISOINDOLINYL DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
| US-7144894-B2 | Sulfonamide bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| US-20060063799-A1 | Sulfonamide bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173886-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | OPRM1, OPRK1, OPRD1 | PARP10 3869/4885PARP11 4109/4885PIM1 4319/4885 |
| US-20060063799-A1 | Sulfonamide bicyclic compounds | APP, BACE1, IAPP | PARP10 3549/4885PARP11 2838/4885PIM1 1008/4885 |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | PARP10 2728/4885PARP11 2042/4885PIM1 4603/4885 |
| US-20090069300-A1 | ISOQUINOLINYL AND ISOINDOLINYL DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH3, HRH2 | PARP10 2737/4885PARP11 3376/4885PIM1 4362/4885 |
| US-20250296931-A1 | NOVEL ISOQUINOLINONE, PYRROLOPYRIDINONE AND THIENOPYRIDINONE SULFONAMIDE DERIVATIVES | SULT1E1, XDH, PRXL2A | PARP10 1576/4885PARP11 639/4885PIM1 216/4885 |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | PARP10 3171/4885PARP11 2352/4885PIM1 4712/4885 |
| US-20100197725-A1 | 1-OXO-ISOINDOLINE-4-CARBOXAMIDE AND 1-OXO-1,2,3,4-TETRAHYDROISOQUINOLINE-5-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | COX4I1, CNR2, CNR1 | PARP10 650/4885PARP11 288/4885PIM1 1269/4885 |
| US-20240300907-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | PARP10 2728/4885PARP11 2042/4885PIM1 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.